An item appearing in the December issue of Medical Marketing and Media (Pipeline, page 10) incorrectly stated that Biovail’s Ralivia ER (tramadol hydrochloride) had received FDA approval.
Biovail has received an approvable letter from the FDA for the drug, but it has yet to be approved.